{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:54:44Z","timestamp":1772139284889,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.vaccine.2013.07.034","type":"journal-article","created":{"date-parts":[[2013,8,11]],"date-time":"2013-08-11T09:45:11Z","timestamp":1376214311000},"page":"4888-4893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX\u2122 adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques"],"prefix":"10.1016","volume":"31","author":[{"given":"Daniel","family":"DiStefano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Antonello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Bett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneeswara B.","family":"Medi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo R.","family":"Casimiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"ter Meulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.07.034_bib0005","series-title":"Principles of clinical pharmacology","author":"Atkinson","year":"2012"},{"issue":"4","key":"10.1016\/j.vaccine.2013.07.034_bib0010","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2105\/AJPH.80.4.476","article-title":"Rabies vaccine adsorbed: neutralizing antibody titers after three-dose pre-exposure vaccination","volume":"80","author":"Berlin","year":"1990","journal-title":"American Journal of Public Health"},{"issue":"Pt. 6","key":"10.1016\/j.vaccine.2013.07.034_bib0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1099\/0022-1317-70-6-1513","article-title":"Rabies virus-specific human T cell clones provide help for an in vitro antibody response against neutralizing antibody-inducing determinants of the viral glycoprotein","volume":"70","author":"Bunschoten","year":"1989","journal-title":"Journal of General Virology"},{"issue":"4","key":"10.1016\/j.vaccine.2013.07.034_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/hv.3.4.4309","article-title":"Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice","volume":"3","author":"Caulfield","year":"2007","journal-title":"Human Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.07.034_bib0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1128\/jcm.3.2.96-101.1976","article-title":"Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine","volume":"3","author":"Cox","year":"1976","journal-title":"Journal of Clinical Microbiology"},{"issue":"5","key":"10.1016\/j.vaccine.2013.07.034_bib0030","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14760584.6.5.761","article-title":"ISCOMATRIX\u2122 adjuvant for prophylactic and therapeutic vaccines","volume":"6","author":"Drane","year":"2007","journal-title":"Expert Review of Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2013.07.034_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4049\/jimmunol.1004114","article-title":"ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells","volume":"187","author":"Duewell","year":"2011","journal-title":"Journal of Immunology"},{"issue":"7198","key":"10.1016\/j.vaccine.2013.07.034_bib0040","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.vaccine.2013.07.034_bib0045","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2105\/AJPH.56.12.2106","article-title":"Potentiation of tissue culture rabies vaccine by adjuvants","volume":"56","author":"Fenje","year":"1966","journal-title":"American Journal of Public Health and the Nation's Health"},{"issue":"1\/2","key":"10.1016\/j.vaccine.2013.07.034_bib0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.imlet.2012.06.002","article-title":"Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro","volume":"147","author":"Ghimire","year":"2012","journal-title":"Immunology Letters"},{"issue":"5","key":"10.1016\/j.vaccine.2013.07.034_bib0055","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1128\/JVI.72.5.3711-3719.1998","article-title":"Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system","volume":"72","author":"Hooper","year":"1998","journal-title":"Journal of Virology"},{"issue":"23","key":"10.1016\/j.vaccine.2013.07.034_bib0060","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2013.07.034_bib0065","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.vaccine.2009.10.094","article-title":"Immunostimulatory CpG oligonucleotides: effect on gene expression and utility as vaccine adjuvants","volume":"28","author":"Klinman","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2013.07.034_bib0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/004947550003000108","article-title":"Developments in the production and application of rabies vaccine for human use in China","volume":"30","author":"Lin","year":"2000","journal-title":"Tropical Doctor"},{"issue":"8","key":"10.1016\/j.vaccine.2013.07.034_bib0075","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/14712598.2012.691162","article-title":"Preventative childhood vaccination to rabies","volume":"12","author":"Liu","year":"2012","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"9","key":"10.1016\/j.vaccine.2013.07.034_bib0080","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1348-0421.1981.tb00094.x","article-title":"Essential role of T cells in the postexposure prophylaxis of rabies in mice","volume":"25","author":"Mifune","year":"1981","journal-title":"Microbiology and Immunology"},{"issue":"6","key":"10.1016\/j.vaccine.2013.07.034_bib0085","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10875-006-9044-0","article-title":"Detection of cellular immunity to rabies antigens in human vaccinees","volume":"26","author":"Moore","year":"2006","journal-title":"Journal of Clinical Immunology"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0090","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.addr.2004.02.004","article-title":"Current status and potential applications of ISCOMS in veterinary medicine","volume":"56","author":"Morein","year":"2004","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0095","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1099\/jmm.0.040857-0","article-title":"E.ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases","volume":"61","author":"Morelli","year":"2012","journal-title":"Journal of Medical Microbiology"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0100","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1128\/JVI.65.7.3429-3434.1991","article-title":"Role of CD4+ and CD8+ T cells in murine resistance to street rabies virus","volume":"65","author":"Perry","year":"1991","journal-title":"Journal of Virology"},{"issue":"9","key":"10.1016\/j.vaccine.2013.07.034_bib0105","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1021\/jm100177p","article-title":"Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses","volume":"53","author":"Putta","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0110","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1016\/j.vaccine.2008.04.033","article-title":"Reduced dose pre-exposure primary and booster intradermal rabies vaccination with a purified chick embryo cell vaccine (PCECV) is immunogenic and safe in adults","volume":"26","author":"Roukens","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0115","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00006454-199811000-00007","article-title":"Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified vero cell rabies vaccine","volume":"17","author":"Sabchareon","year":"1998","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/649211","article-title":"Postexposure rabies prophylaxis completed in 1 week: preliminary study","volume":"50","author":"Shantavasinkul","year":"2010","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0125","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"Smith","year":"1973","journal-title":"Bulletin of the World Health Organization"},{"issue":"1","key":"10.1016\/j.vaccine.2013.07.034_bib0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cellimm.2010.03.005","article-title":"Synthesis and immunological activities of novel agonists of Toll-like receptor 9","volume":"263","author":"Struthers","year":"2010","journal-title":"Cellular Immunology"},{"issue":"4","key":"10.1016\/j.vaccine.2013.07.034_bib0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4161\/hv.4.4.5588","article-title":"An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax) in Indian subjects","volume":"4","author":"Sudarshan","year":"2008","journal-title":"Human Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0140","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1099\/0022-1317-33-3-535","article-title":"Thymus dependence of rabies vaccine","volume":"33","author":"Turner","year":"1976","journal-title":"Journal of General Virology"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0145","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2008.01.043","article-title":"A CpG oligonucleotide acts as a potent adjuvant for inactivated rabies virus vaccine","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"issue":"8345","key":"10.1016\/j.vaccine.2013.07.034_bib0150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(83)90288-X","article-title":"An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis","volume":"2","author":"Warrell","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmaid.2011.12.005","article-title":"Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure","volume":"10","author":"Warrell","year":"2012","journal-title":"Travel Medicine and Infectious Disease"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0160","first-page":"139","article-title":"Intradermal rabies vaccination: the evolution and future of pre- and post-exposure prophylaxis","volume":"351","author":"Warrell","year":"2012","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0165","first-page":"309","article-title":"WHO Position Paper on Rabies","volume":"85","year":"2010","journal-title":"Weekly Epidemiological Record"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0170","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/cid\/cis389","article-title":"Rabies post-exposure vaccination. Are Antibody Responses Adequate?","volume":"55","author":"Wilde","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.034_bib0175","first-page":"268","article-title":"Vaccine potency requirements for reduced immunization schedules and pre-exposure treatment","volume":"40","author":"Working Group II, WHO Expert Committee","year":"1978","journal-title":"Developments in Biological Standardization"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13009778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13009778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T14:55:00Z","timestamp":1646319300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13009778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":35,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0264410X13009778"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX\u2122 adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}